DPP-4 inhibitors and combined treatment in type 2 diabetes: Re-evaluation of clinical success and safety

Review of Diabetic Studies

Volumn 4, Issue 3, 2007, Pages 126-133

  De Valk, Harold W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

DPP 4 inhibitor; Glycemic control; Incretin analogues; Safety; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE DEHYDROGENASE; INCRETIN; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ADD ON THERAPY; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME INHIBITION; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LOW DRUG DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 37849011200     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2007.4.126     Document Type: Review

References (35)

1. Wild S, Rosglic C, Green A, Sicree R, King H. Global prevalence of diabetes; estimates for the year 2000 and projections for 2030. Diabetes Care 2004. 27:1047-1053.
2. Nathan DM. Finding new treatments for diabetes - how many, how fast ... how good? New Engl J Med 2007. 356:437-440.
3. Gallwitz B. New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev Diabet Stud 2005. 2:61-69.
4. Drucker D, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006. 368:1696-1705.
5. Ahren B. Dipeptidyl peptidase-4 inhibitors. Clinical data and clinical implications. Diabetes Care 2007. 30:1344-1350.
6. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes. Diabetes Care 2007. 30:1335-1343.
7. Creutzfeldt W. The incretin concept today. Diabetologia 1979. 16:75-85.
8. Creutzfeldt W. Entero-insular axis and diabetes mellitus. Horm Metab Res Suppl 1992. 26:13-18.
9. Ahren B, Landin-Olsson, M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004. 89:2078-2084.
10. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007. 39(3):218-223.
11. Pratley RE, Jauffret-Kramel S, Galbreath E, Holmes D. Twelve-week monotherapy with DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006. 38:423-428.
12. Pi-Sunyer FX, Schweitzer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diab Res Clin Pract 2007. 76:132-138.
13. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006. 29(12):2632-2637.
14. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H, Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes. Diabetologia 2006. 49:2564-2571.
15. Scott R, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients wth type 2 diabetes. Clin Pract 2007. 61:171-180.
16. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF 237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004. 27:2874-2880.
17. Bosi E, Camisaca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007. 30:890-895.
18. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006. 29:2638-2643.
19. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP, Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007. 9:194-205.
20. Hermansen K, Kipnes M. Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitud inadequately controlled on glimepiride alone or glimepiride and metformin. Diabetes Obes Metab 2007. 9:733-745.
21. Rosenstock J, Brazg R, Andryuk PJ, Lu Km Stein P, Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitragliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006. 10:1556-1568.
22. Garber AJ, Schweitzer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007. 9:166-174.
23. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007. 50(6):1148-1155.
24. Dunning BE, Foley JE, Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005. 48:1700-1713.
25. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007. 24:955-961.
26. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care 2007. 30:217-223.
27. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazon compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007. 29:175-185.
28. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, ADOPT Study Group. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. New Engl J Med 2006. 355(23):2427-2443.
29. Riddel MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The Treat-To-Target trial. Randomized addition of glargine of human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003. 26:3080-3086.
30. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med 2007. 356(24):2457-2471.
31. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. New Engl J Med 2007. 356(24):2522-2524.
32. Rosiglitazone: seeking a balanced perspective. Lancet 2007. 369(9576):1834.
33. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007. 289(10):1189-1195.
34. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007.298(10):1180-1188.
35. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. New Engl J Med 2007. 357(1):28-38.